Bayer AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bayer AG with three other
companies in this sector in the United States:
sales of $52.82 billion
of which 55%
was Operating Segment-Global Innovative Phar),
Roche Holding Aktiengesellschaft
of which 77%
was Pharmaceuticals), and
of which 66%
was Innovative Medicines).
Bayer AG reported sales of $51.62 billion
December of 2016.
a very small
increase of 1.0%
versus 2015, when the company's sales were $51.09 billion.
Despite this increase, sales are still
below the level achieved in 2014, when Bayer AG
reported sales of $55.77 billion.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Bayer AG had sales
of $51.05 billion.
Sales of Reconciliations saw an increase
that was more than double the company's growth rate: sales were up
50.1% in 2016, from
$4.41 million to $6.62 million.
Bayer AG also saw significant increases in sales in
Pharmaceuticals and Biological Products (up 19.5% to $18.12 billion)
Not all segments of Bayer AG experienced an increase in sales in 2016:
sales of Consumer Care fell 33.8% to $6.66 billion.
Bayer AG also experienced decreases in sales in
Cropscience (down 4.3% to $10.94 billion)
All Other Segments (down 4.9% to $1.15 billion)